News

Currently, Xtandi is approved for the treatment of patients with mCRPC who have previously received docetaxel chemotherapy. The sNDA is based on the results from the Phase III

In Switzerland, Jetrea will be launched by ThromboGenics’ partner Alcon, a division of Novartis. Jetrea is the first pharmacological treatment for VMT and was approved by the European

Senior Scientific, a division of Manhattan Scientifics, has manufactured nanoparticles primarily to support its NanoMRX cancer detection technology. Now the company is making them available for other applications.

The team at VMBD will use the tool of metabolic engineering to transfer cannabis genetic pathways in microbes representing an alternative route to produce cannabinoids at an affordable

Pharma Two B is following the US Food and Drug Administration’s (FDA) 505(b)(2) registration pathway for P2B001. The study titled A Phase 2B, 12-week multi-center, randomized, double-blind, placebo-controlled,

Each company will bring its specific expertise to the joint venture; GrowLife providing equipment manufacturing while Vape Holdings provides guidance for the process technology and concentrate formulas. Cannabis

The trial is being conducted at UC San Diego Moores Cancer Center. This Phase II G-202 trial will treat up to 34 patients with GBM that has progressed

The claims of the patent (patent number 5479918) cover the use of ADXS-HPV for the treatment of late-stage cervical cancer with a term that extends to 2028. Advaxis

EDGE is the trading and registration platform used by exchanges, brokerage firms and banks in multiple markets throughout the world. Oslo Connect combines the flexibility of the OTC